Brief: Shanghai Bao Pharmaceuticals Says NMPA Approves Human Hyaluronidase For Injection For Marketing
08/04/2026 09:24
April 8 (Reuters) - Shanghai Bao Pharmaceuticals Co Ltd 2659.HK: NMPA APPROVES HUMAN HYALURONIDASE FOR INJECTION (KJ017) FOR MARKETING Further company coverage: 2659.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Bao Pharmaceuticals Co
See all newsBrief: Shanghai Bao Pharmaceuticals Says U.S. FDA Approves IND For Subcutaneous Infusion Of BJ007 For Injection
Brief: Shanghai Bao Pharmaceuticals Says NMPA Accepts NDA For KJL03 For Injection
Brief: Shanghai Bao Pharmaceuticals Says NMPA Approves Human Hyaluronidase For Injection For Marketing
Shanghai Bao at nearly 4-week high on China regulator nod to new product
Brief: Shanghai Bao Pharmaceuticals Proposes To Elect Liu Yanjun, Wang Zheng, Li Cui As Executive Directors